A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma

Summary

To compare the progression free survival of LY2510924 plus sunitinib therapy versus sunitinib in the first-line setting for patients with metastatic clear-cell renal cell carcinoma.

Timeline

Start

2011-08

Primary completion

2014-09

Completion

2017-02

Publications

• Hainsworth JD, Reeves JA, Mace JR, Crane EJ, Hamid O, Stille JR, Flynt A, Roberson S, Polzer J, Arrowsmith ER. A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC). Target Oncol. 2016 Oct;11(5):643-653. doi: 10.1007/s11523-016-0434-9.

Drugs

Indications